Source: The Korea Bizwire

Biognosys: Biognosys Launches Spectronaut 19 and Presents Advances with Its Research Platforms at the ASMS 2024 Annual Conference

Spectronaut® 19 offers significant improvements in identifications, candidate discovery, scalability for large-scale analysis, and support for novel workflows Novel TrueDiscovery® P2 Plasma Enrichment method offers market-leading performance and superior economics for unbiased, deep plasma proteomics New TrueTarget® high-throughput LiP-MS workflow enables large-scale drug target deconvolution screening with improved target identification DigitalProteome database and Proteoverse data exploration tool help [...]The post Biognosys Launches Spectronaut 19 and Presents Advances with Its Research Platforms at the ASMS 2024 Annual Conference appeared first on Be Korea-savvy.

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Oliver Rinner's photo - Co-Founder & CEO of Biognosys

Co-Founder & CEO

Oliver Rinner

CEO Approval Rating

90/100

Read more